Lamet Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 5.55 M
- Revenue Growth -1.84%
- Profit Growth 134.56%
- Ebitda 322.06%
- Net Worth 13.56%
- Total Assets -12.38%
About Lamet Pharma
Lamet Pharma Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 June 2015 (Nine years and eight months 2 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹5.55 M.
Rohini Tiwari and Jaiprakash Tiwari serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24296MH2015PTC265853
- Company No.
265853
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jun 2015
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Lamet Pharma Private Limited offer?
Lamet Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Ointment, Cough Syrup, Diclofenac, Diclofenac Paracetamol Tablet, Pharmaceutical Medicine, Antiparasitic Drug, Albendazole Tablets, Diclofenac Sodium Injection, Pain Reliever Gel.
Who are the key members and board of directors at Lamet Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rohini Tiwari  | Director | 22-Jun-2015 | Current |
| Jaiprakash Tiwari | Director | 31-Jul-2015 | Current |
Financial Performance of Lamet Pharma.
Lamet Pharma Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 1.84% decrease. The company also saw a substantial improvement in profitability, with a 134.56% increase in profit. The company's net worth Soared by an impressive increase of 13.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lamet Pharma?
In 2020, Lamet Pharma had a promoter holding of 75.00% and a public holding of 25.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.55 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.56 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2020 | Others | ₹5.55 M | Open |
How Many Employees Work at Lamet Pharma?
Lamet Pharma has a workforce of 89 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lamet Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lamet Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
